The data demonstrates that naringenin is a non-toxic assembly inhibitor of HCV and that other PPARα agonists play a similar role in blocking viral production.
The combination of naringenin with STAT-C agents could potentially bring a rapid reduction in HCV levels during the early treatment phase, an outcome associated with sustained virological response.
2011-10-19
Eng.
Journal of Hepatology
Center for Engineering in Medicine, Shriners Burns Hospital, Boston, MA, USA.
J Hepatol. 2011 Nov;55(5):963-71
© Galenicom 1999-2013